Executive summary
ImCheck Therapeutics has received €20.18m ($22.35m) in non-dilutive funding from the French government to advance its pipeline.
The funds will be used to support clinical development for ImCheck's lead candidate, ICT01, a pathogen-agnostic γ9δ2 T cell-activating monoclonal antibody targeting BTN2A, also known as CD277. This cancer therapy is being evaluated in multiple solid tumours and blood cancer indications in Phase I/IIa trials.
ImCheck scores $22.4m in French funding to develop cancer antibody – RamaOnHealthcare
About Rama SmartSearch
RamaOnHealthcare brings signal to noise to keep you up-to-date with the latest healthcare industry news. We continuously refine our search algorithm to help you quickly and easily find the most relevant and human-vetted content from the best sources and authors.
Smart Topics: Rama SmartSearch identifies popular industry keywords as "Smart Topics" and searches article titles for related industry keywords.
You may simply combine keywords to narrow search results. Alternatively, you may use the "AND" operator to also combine keywords.
You may use the "OR" operator to broaden search results to match one or more keywords. Alternatively, you may use the "|" operator to also broaden search results.
You may use quotes to find exact matches, where the keywords are matched in order.
You may use the dash operator to exclude keywords and quoted exact matches from search results.
Searching...
Share This Article
ImCheck scores $22.4m in French funding to develop cancer antibody
Clinical Trials Arena August 30, 2024
Phalguni Deswal
The French government funds will support clinical development for T cell-activating monoclonal antibody and another project.
ImCheck Therapeutics has received €20.18m ($22.35m) in non-dilutive funding from the French government to advance its pipeline.
The funds were disbursed as part of the “i-Démo” call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. The public capital will be used to advance ImCheck’s clinical pipeline consisting of a T cell-activating monoclonal antibody and an infectious disease therapy.
The French company’s lead candidate is ICT01, a pathogen-agnostic γ9δ2 T cell-activating monoclonal antibody targeting BTN2A, also known as CD277. It is being evaluated in multiple solid tumours and blood cancer indications in Phase I/IIa trials.
The company...
Today's Sponsor
